Literature DB >> 571890

Antibody-dependent cell-mediated cytotoxicity against cells infected with respiratory syncytial virus: characterization of in vitro and in vivo properties.

H Meguro, M Kervina, P F Wright.   

Abstract

An in vitro 51Cr release assay for human antibody-dependent cell-mediated cytotoxicity (ADCC) against HeLa cells infected with respiratory syncytial virus (RSV) has been characterized by using leukophoresed and adherent cell-depleted adult lymphocytes. Lymphoytes from RSV seronegative children were also competent as effector cells. Sera from children with :1) primary and recurrent natural RSV infections, or 2) live attenuated RSV vaccine infection were examined to characterize the behavior of ADCC antibody in vivo. After natural RSV infection ADCC antibody rose and fell more rapidly than neutralizing antibody. In two children undergoing primary RSV infection with attenuated vaccine, neutralizing antibody was formed in the absence of detectable ADCC antibody. The nonparallel behavior of ADCC and neutralizing antibodies suggests the heterogeneity of either the antigen involved or the mechanism of antibody production in the two antibody systems.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 571890

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.

Authors:  Zelda Euler; Galit Alter
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 2.  Respiratory syncytial virus. Brief review.

Authors:  E J Stott; G Taylor
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

3.  Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.

Authors:  Xiaoyan Zhan; Karen S Slobod; Bart G Jones; Robert E Sealy; Toru Takimoto; Kelli Boyd; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Int Immunol       Date:  2014-12-04       Impact factor: 4.823

4.  Development of antibody-dependent cell-mediated cytotoxicity in the respiratory tract after natural infection with respiratory syncytial virus.

Authors:  T N Kaul; R C Welliver; P L Ogra
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

5.  Cell-mediated immune response to respiratory syncytial virus infection in owl monkeys.

Authors:  W C Koff; F R Caplan; S Case; S B Halstead
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

6.  Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Authors:  Bart G Jones; Robert E Sealy; Sherri L Surman; Allen Portner; Charles J Russell; Karen S Slobod; Philip R Dormitzer; John DeVincenzo; Julia L Hurwitz
Journal:  Vaccine       Date:  2014-04-14       Impact factor: 3.641

7.  In vitro cell-dependent lysis of respiratory syncytial virus-infected cells mediated by antibody from local respiratory secretions.

Authors:  M P Cranage; P S Gardner; K McIntosh
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

8.  Complement activation by respiratory syncytial virus-infected cells.

Authors:  K M Edwards; P N Snyder; P F Wright
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

Review 9.  Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.

Authors:  Elisabeth A van Erp; Willem Luytjes; Gerben Ferwerda; Puck B van Kasteren
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

Review 10.  Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection.

Authors:  D C Merz; A Scheid; P W Choppin
Journal:  J Exp Med       Date:  1980-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.